Abstract 1744P
Background
Some studies have suggested a higher risk of respiratory complications related to COVID-19 (C-19) in cancer patients (pts), but there is a lack of knowledge concerning the outcomes and prognostic factors. We evaluated whether various factors can predict a more serious C-19 infection.
Methods
We conducted a retrospective study including 51 pts diagnosed of C-19 between March 10 and April 7, 2020. All pts present tumor disease at diagnosis of C-19: advanced disease, neoadjuvant treatment (ttm) or maintenance ttm after definitive chemoradiotherapy. It has been evaluated whether certain factors may present an increased risk for the development of a SCE, defined as death, the need of high oxygen flow (FiO2≥50%), non-invasive or invasive mechanical ventilation or Intensive Care Unit admission. These factors have been age, ECOG, ttm line, type of ttm, time from last ttm to C-19 diagnosis, smoke, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, cardiopathy, body mass index, fever, cough, dyspnea, myalgia, gastrointestinal symptoms, infiltrates in chest radiography, CURB65 ≥1, creatine phosphokinase, lactate dehydrogenase and D-Dimer elevated, lymphopenia and PaO2/FiO2 <300 mmHg.
Results
At the time of the data cut-off on May 16 2020, we have collected 51 cancer pts. Most of them were men (61%) with a median age of 68 years (range 19-86). Lung cancer was the most frequent type of cancer (22%), and the most common ttm was chemotherapy (51%). Eighteen pts (35%) developed a SCE, with 13 deaths (25%). Only dyspnea and PaO2/FiO2 <300 mmHg showed an increased risk to develop a SCE. Table: 1744P
| Odds ratio (95% CI) | p | Hazard ratio for SCE (95% CI) | p | |
| Dyspnea | 5.2 (1.47-18.33) | 0.01 | 3.22 (1.09-9.48) | 0.034 |
| PaO2/FiO2 <300 mmHg | 8.8 (2.23-33.71) | 0.002 | 3.7 (1.34-10.24) | 0.012 |
Conclusions
Despite our retrospective analysis and the limited number of pts, we conclude that advanced cancer pts receiving antitumoral ttm have a higher risk for the development of SCE when considering the presence of PaO2/FiO2 <300 mmHg and dyspnea on admission. Therefore, it is crucial to screen for C-19 infection in any cancer patient who reports dyspnea, given the potential risk of poor evolution.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oncology Department, Hospital Universitario Ramon y Cajal, Madrid.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.